

Global - Cancer Vaccines Market and Pipeline Vaccines Analysis to 2020

<https://marketpublishers.com/r/GA1F7889A70EN.html>

Date: November 2015

Pages: 213

Price: US\$ 1,290.00 (Single User License)

ID: GA1F7889A70EN

Abstracts

The cancer industry is one of the most lucrative business worldwide. Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. Cancer vaccines can be broadly classified into two segments: prophylactic and therapeutic vaccines. Prophylactic vaccines are used for the prevention of cancer, whereas therapeutic vaccines are used for treatment of cancer. With the rising incidences of cancer and limited treatment options, physicians are being forced to look for precautionary vaccines beyond the conventional treatments. As a result, many companies are now investing in developing prophylactic and therapeutic vaccines to curb this deadly disease.

The prophylactic vaccines currently available in the market include Mercks Gardasil and GSKs Cervarix while the only therapeutic vaccine in the market is Dendreon's Provenge. In the global cancer vaccines market, the prophylactic vaccines segment account for maximum share of the market. However, the market share of prophylactic vaccines is likely to decline continuously during the forecasting period due to the increasing uptake of therapeutic vaccines. The market share of therapeutic cancer vaccines is anticipated to increase during the forecasting period.

In the cancer vaccines market, Merck is the clear leader and is expected to maintain its dominance over a longer period of time. Dendreon Corporation is the second leading player in cancer vaccines market accounting for XX% market share in 2014. It is predicted that GSK will account for single digit share of the cancer vaccine market by 2020.

Global Cancer Vaccines Market - Regional Analysis: The United States is the largest regional market for cancer vaccines. United States accounted for XX% share of the

global cancer vaccines market in 2014. The Asian region is the second leading market for cancer vaccines. The European region cancer vaccines market share is anticipated to increase from XX% in 2014 to XX% by the year 2020.

iGATE Research report titled Global - Cancer Vaccines Market and Pipeline Vaccines Analysis to 2020 is a 213 page report with 26 Figures and 25 Tables. This report studies in detail the Global Cancer Vaccines Market, Regional Cancer Vaccines Market, Major Deals and Funding in Cancer Vaccines Industry, Cancer Vaccines Pipeline Products Portfolio, Company Wise Cancer Vaccines Pipeline Products and the driving factors and challenges for the Cancer Vaccines Market.

The Cancer Vaccines Market studied in the report covers the following 7 points:

1. Global - Prophylactic Cancer Vaccines Market to 2020
 - I. Gardasil
 - II. Cervarix
2. Global - Therapeutic Cancer Vaccines Market to 2020
 - I. Provenge
3. Cancer Vaccines Market - Regional Analysis to 2020
 - I. United States - Cancer Vaccines Market
 - II. Europe - Cancer Vaccines Market
 - III. Asia - Cancer Vaccines Market
4. Global Cancer Vaccines Market - Major Deals
5. Global Cancer Vaccines - Funding
6. Global Cancer Vaccines Market - Pipeline Portfolio Analysis
7. Company Cancer Vaccines - Pipeline Analysis

The 12 Cancer Vaccines Pipeline Portfolio covered in the report are as follows

1. Prostavac
2. Neuvax
3. Rindopepimut
4. MVax
5. DCVax-L
6. ProstAtak
7. Talimogene Laherparepvec
8. IMA901
9. Imprime PGG
10. OncoVAX

11. Lucanix
12. DCVAC/PCa

The 34 Companies Pipeline Cancer Vaccines covered in the reports are as follows:

1. Aduro Biotech
2. Advantagene
3. Advaxis
4. Agenus
5. AlphaVax
6. Altor BioScience
7. Argos Therapeutics
8. AVAX Technologies
9. Bavarian Nordic
10. Biothera
11. Celldex Therapeutics
12. CureVac
13. Galena Biopharma
14. Genexine
15. GlobelImmune
16. Gradalis
17. Heat Biologics
18. Immatics
19. ImmunoCellular Therapeutics
20. Inovio Pharmaceuticals
21. ISA Pharmaceuticals
22. Juvaris Biotherapeutics
23. NewLink Genetics
24. Northwest Biotherapeutics
25. NovaRx
26. OncoThyreon
27. Oncovir
28. Oxford BioMedica
29. Prima BioMed
30. Sotio
31. Transgene
32. Ubivac
33. Vaccinogen
34. Vaxon Biotech

Source of Information

iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.

Research Methodologies

Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.

Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government And NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries And Local Councils and a large number of Paid Databases.

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL - CANCER VACCINES MARKET AND FORECAST TO 2020

2.1 Global - Prophylactic Cancer Vaccines Market and Forecast to 2020

2.2 Global - Therapeutic Cancer Vaccines Market and Forecast to 2020

3. GLOBAL - CANCER VACCINES MARKET SHARE AND FORECAST TO 2020

3.1 Global Cancer Vaccines Market Share - By Type

3.2 Global Cancer Vaccines Market - Company Share Analysis

3.3 Cancer Vaccines Market - Regional Share Analysis

4. GLOBAL - PROPHYLACTIC CANCER VACCINES MARKET AND FORECAST TO 2020

4.1 Gardasil Sales and Forecast to 2020

4.2 Cervarix Sales and Forecast to 2020

5. GLOBAL - THERAPEUTICS CANCER VACCINES MARKET AND FORECAST TO 2020

5.1 Provenge Sales and Forecast to 2020

6. CANCER VACCINES MARKET - REGIONAL ANALYSIS

6.1 United States - Cancer Vaccines Market and Forecast to 2020

6.2 Europe - Cancer Vaccines Market and Forecast to 2020

6.3 Asia - Cancer Vaccines Market and Forecast to 2020

7. GLOBAL CANCER VACCINES MARKET - MAJOR DEALS

8. GLOBAL CANCER VACCINES - FUNDING

9. GLOBAL CANCER VACCINES MARKET - PIPELINE PORTFOLIO ANALYSIS

- 9.1 Prostavac
- 9.2 Neuvax
- 9.3 Rindopepimut
- 9.4 MVax
- 9.5 DCVax-L
- 9.6 ProstAtak
- 9.7 Talimogene Laherparepvec
- 9.8 IMA901
- 9.9 Imprime PGG
- 9.10 OncoVAX
- 9.11 Lucanix
- 9.12 DCVAC/PCa

10. COMPANY CANCER VACCINES - PIPELINE ANALYSIS

- 10.1 Aduro Biotech
- 10.2 Advantagene
- 10.3 Advaxis
- 10.4 Agenus
- 10.5 AlphaVax
- 10.6 Altor BioScience
- 10.7 Argos Therapeutics
- 10.8 AVAX Technologies
- 10.9 Bavarian Nordic
- 10.10 Biothera
- 10.11 Celldex Therapeutics
- 10.12 CureVac
- 10.13 Galena Biopharma
- 10.14 Genexine
- 10.15 GlobelImmune
- 10.16 Gradalis
- 10.17 Heat Biologics
- 10.18 Immatix
- 10.19 ImmunoCellular Therapeutics
- 10.20 Inovio Pharmaceuticals
- 10.21 ISA Pharmaceuticals
- 10.22 Juvaris Biotherapeutics
- 10.23 NewLink Genetics
- 10.24 Northwest Biotherapeutics

- 10.25 NovaRx
- 10.26 OncoThyreon
- 10.27 Oncovir
- 10.28 Oxford BioMedica
- 10.29 Prima BioMed
- 10.30 Sotio
- 10.31 Transgene
- 10.32 Ubivac
- 10.33 Vaccinogen
- 10.34 Vaxon Biotech

11. GLOBAL CANCER VACCINES MARKET - DRIVING FACTORS

- 11.1 Increasing Incidence of Cancer
- 11.2 GAVI Model Fuelling Vaccine Manufacturers
 - 11.2.1 The Partnership Model
 - 11.2.2 The Business Model
- 11.3 Global Immunization Vision and Strategy (GIVS)
- 11.4 Growing Vaccine Availability in United States
- 11.5 The Vaccine Injury Compensation Program
- 11.6 The Vaccine Safety Data link Project
- 11.7 Transformation of Vaccine Technologies
- 11.8 Global Vaccine Action Plan by WHO (2011 - 2020)
- 11.9 Continuous Focus on Effective Communication Strategies

12. GLOBAL CANCER VACCINES MARKET - CHALLENGES

- 12.1 Hurdles to Optimal use of Licensed Vaccines
 - 12.1.1 Technical Obstacles
 - 12.1.2 Economic obstacles
 - 12.1.3 Cultural Obstacles
- 12.2 Shortening the Timeline for Vaccine Development
- 12.3 Complexity of Vaccine Development and Approval System Thwarts Product Development
 - 12.3.1 Legal Obstacles
 - 12.3.2 General Technical Barriers
 - 12.3.3 Economic Barriers
 - 12.3.4 Regulatory Barriers
- 12.4 Obstacles in Vaccine Research and Development

12.5 Barriers to New Entrants in the Vaccines Market

List Of Figures

LIST OF FIGURES:

- Figure 2 1: Global - Cancer Vaccines Market (Million US\$), 2007 - 2014
- Figure 2 2: Global - Forecast for Cancer Vaccines Market (Million US\$), 2015 - 2020
- Figure 2 3: Global - Prophylactic Cancer Vaccines Market (Million US\$), 2007 - 2014
- Figure 2 4: Global - Forecast for Prophylactic Cancer Vaccines Market (Million US\$), 2015 - 2020
- Figure 2 5: Global - Therapeutic Cancer Vaccines Market (Million US\$), 2011 - 2014
- Figure 2 6: Global - Forecast for Therapeutic Cancer Vaccines Market (Million US\$), 2015 - 2020
- Figure 3 1: Global - Cancer Vaccines Market Share (Percent), 2011 - 2014
- Figure 3 2: Global - Forecast for Cancer Vaccines Market Share (Percent), 2015 - 2020
- Figure 3 3: By Company - Cancer Vaccines Market Share (Percent), 2011 - 2014
- Figure 3 4: By Company - Forecast for Cancer Vaccines Market Share (Percent), 2015 - 2020
- Figure 3 5: By Region - Cancer Vaccines Market Share (Percent), 2010 - 2014
- Figure 3 6: By Region - Forecast for Cancer Vaccines Market Share (Percent), 2015 - 2020
- Figure 4 1: Global - Gardasil Vaccines Sales (Million US\$), 2007 - 2014
- Figure 4 2: Global - Forecast for Gardasil Vaccines Sales (Million US\$), 2015 - 2020
- Figure 4 3: Global - Cervarix Vaccines Sales (Million US\$), 2007 - 2014
- Figure 4 4: Global - Forecast for Cervarix Vaccines Sales (Million US\$), 2015 - 2020
- Figure 5 1: Global - Provenge Vaccines Sales (Million US\$), 2011 - 2014
- Figure 5 2: Global - Forecast for Provenge Vaccines Sales (Million US\$), 2015 - 2020
- Figure 6 1: United States - Cancer Vaccines Market (Million US\$), 2010 - 2014
- Figure 6 2: United States - Forecast for Cancer Vaccines Market (Million US\$), 2015 - 2020
- Figure 6 3: Europe - Cancer Vaccines Market (Million US\$), 2010 - 2014
- Figure 6 4: Europe - Forecast for Cancer Vaccines Market (Million US\$), 2015 - 2020
- Figure 6 5: Asia - Cancer Vaccines Market (Million US\$), 2010 - 2014
- Figure 6 6: Asia - Forecast for Cancer Vaccines Market (Million US\$), 2015 - 2020
- Figure 11 1: Global - Estimated Number of Cancer Incidence Cases (Number), 2009 - 2015
- Figure 11 2: US - Number of Retail Clinics offering Vaccination (Number), 2007 - 2012

List Of Tables

LIST OF TABLES:

- Table 9 1: NovaRx - Clinical Development Pipeline
- Table 10 1: AlphaVax - Clinical Development Pipeline
- Table 10 2: Altor BioScience - Clinical Development Pipeline
- Table 10 3: Argos Therapeutics - Clinical Development Pipeline
- Table 10 4: AVAX Technologies - Clinical Development Pipeline
- Table 10 5: Biothera - Clinical Development Pipeline
- Table 10 6: Celldex Therapeutics - Clinical Development Pipeline
- Table 10 7: CureVac - Clinical Development Pipeline
- Table 10 8: Genexine - Clinical Development Pipeline
- Table 10 9: GlobelImmune - Clinical Development Pipeline
- Table 10 10: Gradalis - Clinical Development Pipeline
- Table 10 11: Heat Biologics - Clinical Development Pipeline
- Table 10 12: ISA Pharmaceuticals - Clinical Development Pipeline
- Table 10 13: ISA101-CervISA - Clinical Study Analysis
- Table 10 14: NewLink Genetics - Clinical Development Pipeline
- Table 10 15: Northwest Biotherapeutics - Clinical Development Pipeline
- Table 10 16: NovaRx - Clinical Development Pipeline
- Table 10 17: Sotio - Clinical Development Pipeline
- Table 10 18: Transgene - Clinical Development Pipeline
- Table 10 19: UbiVac - Clinical Development Pipeline
- Table 10 20: Vaccinogen - ACTIVE Clinical Trial Analysis
- Table 10 21: Vaxon Biotech - Clinical Developmet Pipeline
- Table 11 1: Global - Total Future Deaths Averted through Vaccination (Million), 2011 - 2020
- Table 11 2: Global Goal-Level Indicators, 2015 & 2020
- Table 11 3: Improvement Strategies or Requirements - the Joint Commission and the Project's Collaborating Organizations

I would like to order

Product name: Global - Cancer Vaccines Market and Pipeline Vaccines Analysis to 2020

Product link: <https://marketpublishers.com/r/GA1F7889A70EN.html>

Price: US\$ 1,290.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GA1F7889A70EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970